DACTINOMYCIN by Hikma is synthesis. Approved for part of a multi-phase, combination chemotherapy regimen, nonseminomatous testicular cancer and 6 more indications. First approved in 2010.
Drug data last refreshed 19h ago
synthesis. The cytotoxic activity of dactinomycin has been demonstrated in animal models of different human cancers.
Worked on DACTINOMYCIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity